Objective
to investigate the 3-year clinical outcome of FFR-guided complete revascularisation compared to culprit-only treatment in patients with STEMI and MV-disease
Study
multicentre, randomised (1:2) trial
Population
patients with STEMI and MV-disease undergoing primary PCI
Endpoints
composite of all-cause mortality, non-fatal MI, any revascularisation and cerebrovascular events (MACCE) at 3 years (this was a secondary endpoint)
Conclusion
FFR-guided complete revascularisation of patients with STEMI and MV-disease reduced the 3-year revascularisation rate compared to infarct related artery only treatment but did not reduce all-cause mortality and non-fatal re-myocardial infarction
Smits et al. EuroIntervention. 2020;16:225-32
